News and views
Our magazine
Insights gives you all the news from the labs, hot topics, health tips and personal stories. Available as a free monthly email or twice-yearly magazine.
Sign up for more news and views
Campaigning
We want men with prostate cancer to get better diagnosis, better treatment and better support. But we can’t do it alone: we need your help.
Join the fightAbiraterone extends the lives of men like Robert, but it could be rejected for future use. We stand with him and 4,300 others to ask why.
Drug companies and NICE must put their differences aside and think of the men and families at the centre of all this.
Men, we are with you through Covid19: 7 ways we’re working for men during the pandemic.
Research labs were closed, men had their treatments delayed, and much of our activity grinded to a halt, but prostate cancer didn’t, so neither did we.
A year of leaps: 2019 was historic for prostate cancer research
The last year saw the announcement of the world’s first precision medicine for prostate cancer and huge progress towards the development of a home urine test. Just some of the things that made 2019 one of the most innovative years in prostate cancer research history.
NICE decision on abiraterone could take away best hope for some men with incurable disease
BLOG: Abiraterone should continue to be available on the NHS and opened up to all men with newly diagnosed advanced prostated cancer, argues our policy manager Tim Windle, as the UK’s drug guidelines body is set to rule on the future of the treatment.
Hormone therapy shortage should only last a few months says drugs industry body
After we investigated complaints from men unable to get hold of the off-patent prostate cancer drug, bicalutamide, the British Generic Manufacturers' Association has told us problems with supply shouldn't last long.
Study finds early docetaxel and abiraterone equally effective
Prostate Cancer UK welcomes new data from the STAMPEDE trial that clarifies there is no difference in the benefits offered by both treatments for men newly diagnosed with advanced disease, but now we want the option of earlier abiraterone made available to all men.
New STAMPEDE trial results show earlier abiraterone could improve survival of men with advanced prostate cancer
Announced by researchers at a cancer conference in Chicago, the new findings show earlier and combined use of existing treatments can have a significant impact on advanced disease, but questions remain about its suitability for all men.
Behind the Headlines: Does hormone therapy really increase your risk of dementia?
Following reports in the press yesterday of a US study into androgen deprivation therapy – a commonly used treatment for men with prostate cancer in the UK – Prostate Cancer UK's Dr Iain Le Guilliou investigates whether there's any solid proof behind claims it could double the risk of dementia.
New link between testosterone and cancer cell aggression discovered
Prostate Cancer UK and the Movember Foundation reveals new opportunities for diagnosing and treating aggressive prostate cancer
Degarelix approved for men in England whose cancer has spread to the spine
Today’s approval of the hormone therapy, degarelix, by NICE expands on the decision made in 2014 to make it only available to those men who have already developed the symptoms of spinal cord compression. Now, men whose prostate cancer has spread to their spine and who could be at risk of this condition can also access this treatment.